| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| License and other revenue (includes 171 and 81 from a related party for the three months ended september 30, 2025 and 2024, respectively, and 655and 237 for the nine months ended september 30, 2025 and 2024, respectively) | 201 | 492 | 2,330 | 1,038 |
| Cost of goods sold | 0 | 0 | 248 | - |
| Research and development (includes 255 and 473 to a related party for the three and nine months ended september 30, 2024, respectively) | 2,933 | 1,584 | 4,463 | 4,128 |
| General and administrative | 4,308 | 2,476 | 2,824 | 2,844 |
| Total operating expenses | 7,241 | 4,060 | 7,535 | 6,972 |
| Other nonoperating income | - | - | - | 365 |
| Loss from operations | -7,040 | -3,568 | -5,205 | -5,934 |
| Interest income | 65 | 115 | 163 | 338 |
| Other income, net | 3,573 | 1,720 | 207 | - |
| Non-cash interest expense on liability related to the sales of future royalties | 2,570 | 2,762 | 2,673 | 2,457 |
| Loss before income taxes | -5,972 | -4,495 | -7,508 | - |
| Income tax expense | 0 | 0 | 715 | - |
| Net loss | -5,972 | -4,495 | -8,223 | -7,688 |
| Unrealized gain on available-for-sale investments | - | - | - | 6 |
| Other comprehensive income (loss), tax | - | - | - | 7,682 |
| Net loss per share of common stock - basic | -1.14 | -0.06 | -0.11 | -0.1 |
| Net loss per share of common stock - diluted | -1.14 | -0.06 | -0.11 | -0.1 |
| Weighted average shares outstanding - basic | 5,233,981 | 77,844,055 | 76,921,843 | 74,745,415 |
| Weighted average shares outstanding - diluted | 5,233,981 | 77,844,055 | 76,921,843 | 74,745,415 |
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. (CLSD)